Brought to you by:
BEST-CLI: Trial results endure in analysis of patients who presented with diabetes
Diabetes affects approximately 70% of patients with chronic limb-threatening ischemia (CLTI) and is associated with more severe presentation, driven mostly by higher rates of wounds and infections, according to a recently presented retrospective analysis of BEST-CLI randomized controlled trial data.…
Incorporation of Shockwave E8 Peripheral IVL into the treatment of patients with chronic limb-threatening ischemia
This advertorial is sponsored by Shockwave Medical. Anand Prasad, MD, an 18-year veteran of vascular and endovascular medicine with a particular interest in peripheral arterial disease (PAD) in patients with chronic kidney disease (CKD), explores the deliverability of the Shockwave…
Research suggests arm vein is the best alternative bypass conduit to GSV in patients with CLTI
A new analysis has found arm vein to be the most suitable alternative conduit to great saphenous vein (GSV) in chronic limb-threatening ischemia (CLTI) patients, particularly in below-knee bypass targets. Prosthetic grafts also represent an adequate option, the researchers add,…
The top 10 most popular Vascular Specialist stories of October 2024
In October, the most read stories from Vascular Specialist included a new leadership announcement from the American College of Surgeons (ACS); study results examining a potential link between strenuous physical activity and increased venous thromboembolism (VTE) risk in men; the publication…
Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for below-the-knee arteries
Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstrate the long-term effectiveness of the US Food and Drug Administration (FDA)-approved Esprit BTK everolimus-eluting resorbable scaffold system (Abbott Vascular) in patients with the most severe form…
FDA grants R3 Vascular IDE approval for ELITE-BTK pivotal trial of Magnitude drug-eluting bioresorbable scaffold
R3 Vascular today announced that the Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval to initiate its ELITE-BTK pivotal trial of the next-generation Magnitude drug-eluting bioresorbable scaffold for below-the-knee (BTK) peripheral arterial disease (PAD). “We are…
TCT 2024: Drug-eluting resorbable scaffold proves cost effective at one year in LIFE-BTK analysis
A retrospective economic analysis of the LIFE-BTK trial has demonstrated the one-year cost-effectiveness of an everolimus-eluting resorbable scaffold over angioplasty for the treatment of infrapopliteal artery disease, with investigators predicting more significant results in the longer term. Sharing this finding…
Endoscopic vein harvest under the microscope
Conflicting results open fresh debate around effect of vein harvesting technique on long-term patency of lower extremity bypass grafts. Two separate analyses that looked at the impact made by the method used to harvest great saphenous vein (GSV) on the…
The Shockwave E8 experience: Featuring the new Shockwave peripheral IVL workhorse
This advertorial is sponsored by Shockwave Medical. Paul J. Foley III, MD, a vascular surgeon and director of the non-invasive vascular lab at Doylestown Hospital in Doylestown, Pennsylvania, and adjunct associate professor of surgery at the University of Pennsylvania in…
Smoking: BEST-CLI trial points to protective effect against MALE in those undergoing open bypass over endovascular intervention
An analysis of the BEST-CLI randomized controlled trial (RCT) found that smokers with chronic limb-threatening ischemia (CLTI) should be preferentially treated with open bypass over endovascular intervention. Researchers from the University of California San Diego (UCSD) looked at BEST-CLI patients…